CL2018000220A1 - Novedosa composicion oral dual de liberación retardada de dexlansoprazol - Google Patents

Novedosa composicion oral dual de liberación retardada de dexlansoprazol

Info

Publication number
CL2018000220A1
CL2018000220A1 CL2018000220A CL2018000220A CL2018000220A1 CL 2018000220 A1 CL2018000220 A1 CL 2018000220A1 CL 2018000220 A CL2018000220 A CL 2018000220A CL 2018000220 A CL2018000220 A CL 2018000220A CL 2018000220 A1 CL2018000220 A1 CL 2018000220A1
Authority
CL
Chile
Prior art keywords
dexlansoprazole
delayed release
release composition
pharmaceutically acceptable
oral delayed
Prior art date
Application number
CL2018000220A
Other languages
English (en)
Spanish (es)
Inventor
Anwar Siraj Daud
Shamsuddin Jamaluddin
Original Assignee
Zim Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57884420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018000220(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zim Laboratories Ltd filed Critical Zim Laboratories Ltd
Publication of CL2018000220A1 publication Critical patent/CL2018000220A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2018000220A 2015-07-28 2018-01-26 Novedosa composicion oral dual de liberación retardada de dexlansoprazol CL2018000220A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2851MU2015 2015-07-28

Publications (1)

Publication Number Publication Date
CL2018000220A1 true CL2018000220A1 (es) 2018-07-20

Family

ID=57884420

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000220A CL2018000220A1 (es) 2015-07-28 2018-01-26 Novedosa composicion oral dual de liberación retardada de dexlansoprazol

Country Status (6)

Country Link
EP (1) EP3328364A4 (fr)
BR (1) BR112018001539A2 (fr)
CL (1) CL2018000220A1 (fr)
CO (1) CO2018002046A2 (fr)
PE (1) PE20181012A1 (fr)
WO (1) WO2017017615A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102727681B1 (ko) * 2019-02-08 2024-11-07 주식회사유한양행 덱스란소프라졸 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 경구투여용 약학 제제
CN111991367A (zh) * 2020-09-21 2020-11-27 青岛吉达巴尔国际贸易有限公司 一种埃索美拉唑镁脉冲微丸胶囊剂及制备方法
KR102471545B1 (ko) * 2020-11-20 2022-11-29 서울대학교 산학협력단 덱스란소프라졸을 유효성분으로 포함하는 pH 의존성 타블렛-인-캡슐 복합제제 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117756A2 (fr) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Formulations pharmaceutiques de benzimidazole substitué
US20120058194A1 (en) * 2010-08-27 2012-03-08 Navin Vaya Pharmaceutical formulations comprising substituted benzimidazole derivatives
WO2013111149A1 (fr) * 2011-12-21 2013-08-01 Hetero Research Foundation Compositions orales solides à libération contrôlée de dexlansoprazole

Also Published As

Publication number Publication date
EP3328364A1 (fr) 2018-06-06
PE20181012A1 (es) 2018-06-26
EP3328364A4 (fr) 2019-01-02
WO2017017615A1 (fr) 2017-02-02
BR112018001539A2 (pt) 2018-09-18
CO2018002046A2 (es) 2018-02-28

Similar Documents

Publication Publication Date Title
CL2017003320A1 (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
ZA202103587B (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
HRP20201812T1 (hr) Modulatori proteina jezgre hepatitisa b
CY1119645T1 (el) Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
BR112018071585A2 (pt) formulações de um inibidor de lsd1
IL253995A0 (en) Pharmaceutical formulations of proton tyrosine kinase inhibitor
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
AR128816A2 (es) Formas de dosificación farmacéutica de perlas de cisteamina
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX385518B (es) FORMULACIÓN QUE TIENE CARACTERÍSTICAS MEJORADAS DE LIBERACIÓN DE FÁRMACOS pH DEPENDIENTES, QUE CONTIENEN ESOMEPRAZOL O UNA DE SUS SALES FARMACÉUTICAS ACEPTABLE.
WO2015173701A3 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
CL2018000220A1 (es) Novedosa composicion oral dual de liberación retardada de dexlansoprazol
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
CO2020006552A2 (es) Composiciones farmaceuticas que comprenden safinamida
JOP20200005B1 (ar) تركيبات صيدلية
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CO2019006693A2 (es) Composición mejorada de lansoprazol y simeticona y proceso para prepararla
MA41643A (fr) Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton